Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHR A2102

Next Previous
Drug Profile

SHR A2102

Alternative Names: SHR-A2102

Latest Information Update: 26 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Hengrui Pharmaceutical
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Urogenital cancer
  • Phase II/III Bladder cancer
  • Phase II Gynaecological cancer; Non-small cell lung cancer; Solid tumours
  • Phase I/II Squamous cell cancer

Most Recent Events

  • 18 Feb 2026 Suzhou Suncadia Bio pharmaceutical plans a phase III trial for Cervical cancer (Metastatic disease, Recurrent, Second-line therapy or greater) in China (Injection), in March 2026 (NCT07418749)
  • 12 Feb 2026 Phase-III clinical trials in Urogenital cancer (First-line therapy, Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (IV) (NCT07393542)
  • 06 Feb 2026 Suzhou Suncadia Bio pharmaceutical plans a phase III NEC-UC2 trial for the treatment of Urogenital cancer (Late-satge disease, Metastatic disease, First line therapy, Combination therapy, Inoperable/Unresectable) in China (IV), in February 2026 (NCT07393542)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top